Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential impact on CKD.

Weight loss jabs are now are now available on the NHS for those with a prescription. But a black market for the in-demand drugs is springing up on social media - the M.E.N's Nicole Wootton-Cane investigates.

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%. The trial was testing a 7.2 milligram dose of the drug,

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight loss treatment. It has shown remarkable results in reducing body weight, making it a popular choice for those struggling with obesity or overweight.

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially approved for managing type 2 diabetes. While there is currently limited data on its risks and benefits for those with type 1 diabetes,

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act. | The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act.

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the company said semaglutide 7.2 milligram (mg) injections over a 72-week period resulted in an average weight loss of 20.7%, better than the 17.5% weight loss achieved in a prior trial of semaglutide 2.4 mg injections.

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its blockbuster obesity drug Wegovy, helped overweight patients lower their weight by 20.

Weight-loss drugs have been rolled out by the NHS, but many are buying them through social media and online pharmacies instead.